Novo Nordisk AS (HAM:NOVA) Tariff Resilience Score: 8/10 (As of Jul. 04, 2026)


HAM:NOVA Novo Nordisk AS HAM:NOVA
83 GF Score
Price €43.94
GF Value €121.46
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Tariff Resilience Score?

Novo Nordisk AS HAM:NOVA +2.90% 83 Tariff Resilience Score is 8 as of Jul. 04, 2026. GuruFocus rates HAM:NOVA with a GF Score™ of 83/100 and a GF Value™ of €121.46 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Novo Nordisk AS ranks better than 99.61% on this metric.

Novo Nordisk AS has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Novo Nordisk AS has Novo Nordisk has a global manufacturing footprint and strong pricing power in pharmaceuticals, reducing tariff impact. Industry-specific exemptions further enhance resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Novo Nordisk AS might have Highly Resilient.

Novo Nordisk AS  (HAM:NOVA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Novo Nordisk AS Tariff Resilience Score Related Terms

HAM:NOVA vs LLY, JNJ, ABBV: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk AS Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Tariff Resilience Score falls into.


HAM:NOVA
83GF Score
Novo Nordisk AS HAM:NOVA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Novo Nordisk AS (HAM:NOVA) has a Tariff Resilience Score of 8 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Novo Nordisk AS ranks #4 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Novo Nordisk AS's Tariff Resilience Score too high?
Novo Nordisk AS's current Tariff Resilience Score is 8. Based on the distribution chart, Novo Nordisk AS ranks #4 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Tariff Resilience Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #4 out of 1030 companies for Tariff Resilience Score. This places Novo Nordisk AS in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Novo Nordisk AS's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (HAM:NOVA) is currently considered Significantly Undervalued. The stock's GF Value™ is €121.46, compared to a current price of €43.94 — trading 63.8% below its estimated fair value. The current Tariff Resilience Score is 8. Novo Nordisk AS's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Novo Nordisk AS (HAM:NOVA), the current Tariff Resilience Score is 8 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (HAM:NOVA) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €43.94 is trading 63.8% below its estimated GF Value™ of €121.46. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for HAM:NOVA:

  • Tariff Resilience Score: 8
  • GF Value™: €121.46 vs. price of €43.94 (63.8% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the HAM:NOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
83GF Score

Get the complete analysis for HAM:NOVA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.94
Price
€121.46
GF Value